Greenwich LifeSciences, Inc. (GLSI) stock
GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.70+4.94 (+35.90%)
Close on Nov 17, 2026Market cap $274.48MP/E –Yield –
Greenwich LifeSciences total assets
Total assets on the balance sheet at the end of each period.
Greenwich LifeSciences's total assets was $8.88M at Jun 30, 2026. For fiscal 2025 it was $6.18M, up 50.9% from the year before. The highest annual figure on record is $28.68M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.18M | +50.9% |
| FY2024 | Dec 31, 2024 | $4.09M | -41.5% |
| FY2023 | Dec 31, 2023 | $6.99M | -48.1% |
| FY2022 | Dec 31, 2022 | $13.48M | -50.5% |
| FY2021 | Dec 31, 2021 | $27.22M | -5.1% |
| FY2020 | Dec 31, 2020 | $28.68M | +107419.8% |
| FY2019 | Dec 31, 2019 | $26.67K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.88M | +184.0% |
| Q1 FY2026 | Mar 31, 2026 | $10.51M | +281.9% |
| Q4 FY2025 | Dec 31, 2025 | $6.18M | +50.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.81M | -34.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.13M | -56.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.75M | -50.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.09M | -41.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.83M | -36.3% |
| Q2 FY2024 | Jun 30, 2024 | $7.23M | -34.0% |
| Q1 FY2024 | Mar 31, 2024 | $5.51M | -53.8% |
| Q4 FY2023 | Dec 31, 2023 | $6.99M | -48.1% |
| Q3 FY2023 | Sep 30, 2023 | $9.15M | -41.5% |
| Q2 FY2023 | Jun 30, 2023 | $10.95M | -36.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.92M | -39.7% |
| Q4 FY2022 | Dec 31, 2022 | $13.48M | -50.5% |
| Q3 FY2022 | Sep 30, 2022 | $15.65M | -45.9% |
| Q2 FY2022 | Jun 30, 2022 | $17.20M | -42.3% |
| Q1 FY2022 | Mar 31, 2022 | $19.75M | -35.1% |
| Q4 FY2021 | Dec 31, 2021 | $27.22M | -5.1% |
| Q3 FY2021 | Sep 30, 2021 | $28.92M | +360.9% |
| Q2 FY2021 | Jun 30, 2021 | $29.82M | +111688.3% |
| Q1 FY2021 | Mar 31, 2021 | $30.42M | – |
| Q4 FY2020 | Dec 31, 2020 | $28.68M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.27M | – |
| Q4 FY2019 | Dec 31, 2019 | $26.67K | – |
See a number that looks wrong?